LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Saxenda is a brand-name injectable solution prescribed for long-term weight management in adults and some children. It contains the active ingredient liraglutide. Saxenda is not safe to use during ...

Tirzepatide may be more effective than semaglutide or liraglutide for weight loss, as it has a dual mechanism of action.

is pleased to announce the engagement of a contract research organization ("CRO") to design and execute a human pilot study evaluating DehydraTECH-liraglutide against Saxenda® injectable liraglutide.

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Drugs for weight loss like liraglutide (Saxenda, Victoza) have been around for years, with newer arrivals like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) offering an even ...